Trial Profile
Match Pair Analysis Study, Comparing Toxicities Between 2 Treatment Regiments Including Neo-adjuvant Hormonal Therapy Plus Hypofractionated RT With HDR Brachytherapy Boost Compare to Our Current Clinical Standard Approach at CHU de Quebec
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 Mar 2024
Price :
$35
*
At a glance
- Drugs Degarelix (Primary) ; LHRH receptor agonists
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms HyBraFi
- 19 Mar 2024 Planned End Date changed from 1 Jun 2023 to 1 Jun 2025.
- 19 Mar 2024 Planned primary completion date changed from 1 May 2015 to 1 Jun 2024.
- 05 Apr 2023 Planned End Date changed from 1 Jul 2018 to 1 Jun 2023.